An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30; Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT01542424

NN304-1763

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.

Enrollment: 1,889 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Macedonian people with diabetes mellitus (Type 1 or Type 2)

Trial design

1,889 participants in 2 patient groups

BIAsp 30 users

Treatment:

Drug: biphasic insulin aspart 30

IDet users

Treatment:

Drug: insulin detemir